GIP and Genetic obesity: With many new pharmacotherapeutical options available soon, such as the long-acting GLP-1 analogue semaglutide, dual GIP/GLP-1 receptor agonist tirzepatide, triple agonist GLP-1/GIP/glucagon retratutide, and many others, new studies investigating the effects of these agents in patients with genetic obesity are needed.